LongeveronNASDAQ: LGVN

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in April 2024. The resale of the shares of Class A common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No.

The clinical-stage biotech market is as vast as it is complicated. Companies operating in this space are wide-ranging in the illnesses they look to treat.

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the BIO International Convention taking place June 3-6, 2024 at the San Diego Convention Center. At the conference, members of the Longeveron management team will host meetings with global pharmaceutical company executives to explore potential partnership and strategic opportunities for the Company's Alzheimer's disease program, which has generated positive data in successful Phase 1 and Phase 2 clinical trials.

Longeveron Inc. (NASDAQ:LGVN) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 5:00 PM ET. Participants include Derek Cole, Wa'el Hashad, Nataliya Agafonova, Lisa Locklear, and Joshua Hare. The call will be moderated by Ram Selvaraju from H.C. Wainwright. Welcome to Longeveron's 2024 First Quarter Financial Results Earnings Call.

Longeveron Inc., a biotechnology company focused on regenerative medicines, will release its financial results for the first quarter of 2024 and give a business update on May 14, 2024 after the U.S. financial markets close. The Company will also hold a conference call and webcast at 5:00 p.m. on the same day.

Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript

Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial of its Alzheimer's treatment Lomecel-B.

Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa'el Hashad - Chief Executive Officer Nataliya Agafonova - Chief Medical Officer Lisa Locklear - Chief Financial Officer Joshua Hare - Co-Founder, Chief Science Officer and Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Greetings, and welcome to the Longeveron's Second Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode.